IFI44 is identified as a key biomarker and molecular target for immune escape in RA patients with COVID-19 or S. aureus infections, with 1,25-Dihydroxy vitamin D3 suggested as a potential therapeutic agent.
Answers are grounded in this paper and cite their sources.
IFI44 merits validation as a shared target in RA with infections; leaves open therapeutic translation pending prospective trials.
IFI144 was discovered as a shared biomarker and disease target for RA, COVID-19, and SAB by this study. IFI44 negatively regulates the IFN signaling pathway to promote viral replication and bacterial proliferation and is an important molecular target for SARS-CoV-2 and S. aureus immune escape in RA. Dendritic cells play an important role in this process. 1,25-Dihydroxy vitamin D3 may be an important therapeutic agent in treating RA with SARS-CoV-2 and S. aureus infections.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: